(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.08%) $0.927
(0.28%) $10.87
(0.07%) $0.793
(-0.32%) $92.28
-0.89% ¥ 2 904.00
Live Chart Being Loaded With Signals
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan...
Stats | |
---|---|
Today's Volume | 162 000 |
Average Volume | 189 364 |
Market Cap | 142.93B |
EPS | ¥0 ( 2024-02-12 ) |
Next earnings date | ( ¥38.66 ) 2024-05-12 |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 12.18 |
ATR14 | ¥1.903 (0.07%) |
Volume Correlation
Towa Pharmaceutical Co., Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Towa Pharmaceutical Co., Correlation - Currency/Commodity
Towa Pharmaceutical Co., Financials
Annual | 2022 |
Revenue: | ¥208.86B |
Gross Profit: | ¥72.71B (34.81 %) |
EPS: | ¥44.72 |
Q3 | 2023 |
Revenue: | ¥60.93B |
Gross Profit: | ¥22.17B (36.38 %) |
EPS: | ¥92.75 |
Q2 | 2023 |
Revenue: | ¥52.85B |
Gross Profit: | ¥18.23B (34.50 %) |
EPS: | ¥44.76 |
Q1 | 2023 |
Revenue: | ¥54.55B |
Gross Profit: | ¥20.01B (36.68 %) |
EPS: | ¥96.50 |
Financial Reports:
No articles found.
Towa Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥30.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.667 | 2005-03-28 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 38 | -- |
Total Paid Out | ¥541.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.37 | -- |
Div. Sustainability Score | 9.24 | |
Div.Growth Potential Score | 4.04 | |
Div. Directional Score | 6.64 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9369.T | Ex Dividend Junior | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
8367.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7803.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
6981.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6368.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5332.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4398.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3591.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2813.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
1515.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0496 | 1.500 | 9.01 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0283 | 1.200 | 9.06 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0814 | 1.500 | -0.207 | -0.310 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.77 | 0.800 | 1.148 | 0.919 | [1 - 3] |
quickRatioTTM | 1.173 | 0.800 | 7.81 | 6.25 | [0.8 - 2.5] |
cashRatioTTM | 0.399 | 1.500 | 8.89 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.473 | -1.500 | 2.12 | -3.17 | [0 - 0.6] |
interestCoverageTTM | 16.44 | 1.000 | 5.02 | 5.02 | [3 - 30] |
operatingCashFlowPerShareTTM | 821.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 821.31 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.318 | -1.500 | 4.73 | -7.09 | [0 - 2.5] |
grossProfitMarginTTM | 0.347 | 1.000 | 7.56 | 7.56 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0564 | 1.000 | -0.871 | -0.871 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.206 | 1.000 | 9.97 | 9.97 | [0.2 - 2] |
assetTurnoverTTM | 0.571 | 0.800 | 9.53 | 7.62 | [0.5 - 2] |
Total Score | 9.24 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 12.06 | 1.000 | 8.88 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0814 | 2.50 | -0.133 | -0.310 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 821.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.13 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 821.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.140 | 1.500 | -4.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.171 | 1.000 | 8.23 | 0 | [0.1 - 0.5] |
Total Score | 4.04 |
Towa Pharmaceutical Co.,
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators